Description: This study of socioeconomic inequalities in mortality builds on a previous report in which we identified a large and growing gradient in life expectancy between 1982 and 2019 across U.S. counties classified into 10 socioeconomically homogeneous categories. In this report, we seek to identify the particular causes of death contributing to the growing disadvantage in mortality between populations in the least and most affluent deciles as previously defined.

Description: This webcast will update listeners on the financial status of the U.S. Social Security program, describe half a dozen widespread myths, and discuss the reality of "waste, fraud and abuse" in the program.

Description: It's your first full day of productive learning! Start it off right with a delicious breakfast and warm welcome.

Description: IFRS 17 is transforming insurance financial reporting around the world, and Latin American markets are at different stages of adoption and implementation. This webinar will provide an overview of the IFRS 17 standard and explore its practical implications for insurers in Latin America, with a particular focus on current practice and industry experience. This webinar is for actuaries, actuarial teams, and other supporting roles working with IFRI reporting requirements and IFRS 17 reporting standards applicable to insurance products. The discussion will be of interest to actuaries and other professionals working in or with insurance companies, especially in Latin America and other Spanish speaking markets, including those in life, general insurance (P&C), health, and reinsurance. The content is suitable for a wide range of experience levels, from early career to senior practitioners with responsibility for financial reporting, valuation, or risk management under IFRS 17. If you are IFRS implementer regardless of the stage of implementation or an IFRS practitioner, this session is for you! Come learn about the resources from the SOA that can support your work, including an IFRI Certificate that offers a recognition of your skills and knowledge of this area. There will be an opportunity to ask questions in the Q & A part of the session. The webinar will be conducted in English with an option to submit questions in English or Spanish. Learning outcomes By the end of the webinar, participants will be able to: Describe the state of IFRS 17 implementation readiness across Latin America. Identify next steps and SOA professional resources to support ongoing IFRS 17 and IFRI reporting work.

Description: This session provides a comprehensive overview of the enhancements to the VM-22 principles-based reserving framework. It features a case study on Fixed Indexed Annuities (FIA) with Guaranteed Minimum Withdrawal Benefits (GMWB), providing a step-by-step attribution analysis that transitions from the current statutory reserve to the new VM-22 reserve, highlighting the assumptions or components influencing the results. The session will also take you along on the journey from a software vendor perspective where we’ll highlight specific VM-22 regulatory changes driving software updates over the last few years, ultimately maintaining alignment with VM-20 and VM-21.

Description: Discuss the dramatically changing provider landscape, as well as the innovative solutions being leveraged by providers to address the intriguing opportunities and complex challenges. Among the questions to be answered are the following: How can providers capitalize on employers’ desire to contract directly with local providers? What's the path for providers to develop employer stop-loss (ESL) capabilities to maximize network value/impact? Can providers create a risk portfolio including ESL for local employers, their own employee plan, and other delegated risk arrangements such as Medicare Advantage? How can captive insurers support a provider's risk strategy?

Description: Session 2A: Navigating Medicaid Single Preferred Drug Lists (PDLs) - A Deep Dive

Description: Medicare Advantage Organizations (MAOs) have made dramatic changes to the benefits and plan premiums they've offered members over the past years. Hear about information on the changes to benefits and plan premiums offered over the past few years. Find out where these strategic items are currently (for CY2024 bid year) and get ideas on what might come in the next few years. Presenters will discuss recent proposals and rules from CMS that will impact the current and future landscape. They will also compare these items in relation to the fee-for-service (FFS) Medicare market. This session will help you gain a deeper knowledge of the Medicare Advantage, Prescription Drug Plan, and Medicare FFS landscape and walk away with some strategic thoughts on potential paths MAOs may take from here.

Description: Explore the value and cost of prescription drugs, how they should be defined and measured and the effects various stakeholders in the pharmacy ecosystem can have on these factors in the latest webcast. You'll investigate the impact of coverage, formulary and rebate negotiations and related benefit design. Find out how actuaries can answer questions related to the prescription drug industry, in addition to improving the access, quality and affordability of prescription drugs in the United States. Join us for this webcast and come learn about value-based contract design, negotiations, implementation and administration for prescription drugs.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.